{"product_id":"ctmx-ansoff-analysis","title":"(CTMX) CytomX Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis CytomX Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is designed for strategy, investment, or planning use. This page contains a real preview\/sample of the actual analysis so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-2009 Phase II breast cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-2009 is already in Phase II for breast cancer, so CytomX Therapeutics, Inc. is penetrating a market it already serves instead of entering a new therapy area. Breast cancer is a major oncology market, with about 2.3 million new cases worldwide in 2022, and antibody-drug conjugates already play a growing role. Advancing CX-2009 can deepen CytomX Therapeutics, Inc. presence in the breast cancer ADC space and support share gain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-2029 Phase II multi-cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-2029 is already being tested across multiple cancers, so CytomX Therapeutics, Inc. can push one existing asset deeper into the same oncology market instead of starting from zero. That is classic market penetration: more use, same customer base.\u003c\/p\u003e\n\u003cp\u003eMulti-indication execution can raise CX-2029’s relevance with oncologists and cancer centers that already follow CytomX Therapeutics, Inc. If the Phase II readouts stay positive, the program can expand share inside current oncology categories without needing a new market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS-986249 Phase I-II metastatic melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMS-986249 is already in Phase I-II, so CytomX Therapeutics, Inc. is not testing the market from scratch; it is pushing deeper into metastatic melanoma, a major oncology use case. In 2025, the American Cancer Society estimated 104,960 new melanoma cases and 8,430 deaths in the U.S., which shows the size of the need. Continued progress can strengthen CytomX Therapeutics, Inc.'s immuno-oncology position and support future partner interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBMS-986288 Phase I solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBMS-986288 is still in Phase I for solid tumors, so CytomX Therapeutics, Inc. is using market penetration, not a new-market push. It deepens presence in an existing core oncology area and keeps the company in front of clinicians and partners while the asset is still early.\u003c\/p\u003e\n\u003cp\u003eBecause solid tumors make up the largest share of oncology drug development, even early Phase I data can preserve strategic visibility. For CytomX Therapeutics, Inc., the value is less about near-term sales and more about staying relevant in a high-value segment where trial momentum matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I only; no commercial revenue yet\u003c\/li\u003e\n\u003cli\u003eExtends solid-tumor footprint\u003c\/li\u003e\n\u003cli\u003eSupports core oncology visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSix-partner Probody alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytomX Therapeutics has six active Probody partners: AbbVie, Amgen, Bristol Myers Squibb, ImmunoGen, Pfizer, and Astellas. That depth supports repeat use of the platform in current oncology programs, which can widen trial scale and speed access inside the same disease areas. In market penetration terms, the model favors reuse over new indication bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSix-partner base broadens oncology reach\u003c\/li\u003e\n\u003cli\u003eReused platform lowers execution friction\u003c\/li\u003e\n\u003cli\u003eShared programs can scale trials faster\u003c\/li\u003e\n\u003cli\u003eExisting disease areas support access gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCytomX Expands Within Oncology With Key Pipeline Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is using market penetration by pushing CX-2009, CX-2029, BMS-986249, and BMS-986288 deeper into oncology markets it already serves, not into new therapy spaces. That fits a reuse-and-expand model, with Phase I-II and Phase II data aimed at stronger share in breast cancer, melanoma, and solid tumors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eMarket signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCX-2009\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eBreast cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS-986249\u003c\/td\u003e\n\u003ctd\u003ePhase I-II\u003c\/td\u003e\n\u003ctd\u003e104,960 U.S. melanoma cases in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS-986288\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eSolid tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing CytomX Therapeutics, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise CytomX Therapeutics Ansoff Matrix to quickly clarify growth options and reduce strategic planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable source list validating CytomX Therapeutics’ Ansoff Matrix growth assumptions for products, markets, and strategic due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-2029 four cancer indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-2029 is being tested in four markets: squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. That is a clear market development move, using one asset to expand beyond a single indication and spread clinical risk across multiple oncology segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-2009 breast cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-2009 targets CD166 and is in Phase II for breast cancer, a new market for CytomX Therapeutics, Inc.’s ADC portfolio. Breast cancer remains the world’s most diagnosed cancer, with about 2.3 million new cases and 670,000 deaths in 2022, so even modest efficacy could matter. Success would add a second oncology segment to the same asset and expand the addressable commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS-986249 metastatic melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMS-986249 moves CytomX’s CTLA-4 Probody into metastatic melanoma, a distinct immuno-oncology market with high unmet need. It broadens clinical exposure beyond earlier tumor settings and supports market development by testing the platform in a new, clinically relevant cancer. In this arena, the benchmark CTLA-4 class is already proven, but safety remains a key differentiator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBMS-986288 solid tumor entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBMS-986288’s move into solid tumors widens CytomX Therapeutics, Inc.’s reach from a narrow cancer setting to a much larger market. Solid tumors account for roughly 90% of adult cancers, and that breadth makes this a classic market development step: one product concept, many tumor types.\u003c\/p\u003e\n\u003cp\u003eAt 2025 year-end, CytomX Therapeutics, Inc. had about $144.5 million in cash, cash equivalents, and marketable securities, which supports longer development work. In a market projected to exceed $200 billion in annual global oncology drug sales, any solid-tumor label expansion can matter more than a single-disease readout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader tumor reach\u003c\/li\u003e\n\u003cli\u003eSingle concept, wider use\u003c\/li\u003e\n\u003cli\u003eStrong fit for market development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led oncology reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. uses six major pharma partners to push oncology programs into more development paths without funding a full sales and commercial build. That partner-led model is a low-capital way to expand reach, share risk, and keep pipeline assets in motion across more tumor programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSix pharma partners extend reach\u003c\/li\u003e\n\u003cli\u003eNo full commercial build needed\u003c\/li\u003e\n\u003cli\u003eShares development and cost risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCytomX Expands One Oncology Platform Across More Cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is extending one oncology platform into new tumor markets, with CX-2029 in 4 indications and BMS-986249 in metastatic melanoma. That fits market development because the same biology is being tested across more cancers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, 2025 year-end\u003c\/td\u003e\n\u003ctd\u003e$144.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCX-2029 indications\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partners\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWith six pharma partners, CytomX Therapeutics, Inc. can widen reach without a full commercial build, and that lowers funding risk.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCytomX Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full Ansoff Matrix report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable Ansoff Matrix version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-2043 epCAM ADC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-2043 is CytomX Therapeutics, Inc.'s conditionally activated epCAM ADC, and it expands the company's oncology pipeline with a new tumor-targeted mechanism. In Ansoff terms, this is product development: a new product for an existing oncology market, aimed at broadening CytomX's addressable cancer franchise. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCX-904 EGFR Probody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCX-904 is a conditionally activated EGFR Probody, so it fits Ansoff’s product development move: a new targeted drug built on CytomX Therapeutics, Inc.’s existing platform. EGFR is one of the most validated cancer targets in oncology, and CX-904 extends the platform into a proven biology lane. CytomX Therapeutics, Inc. has reported no product revenue from CX-904 to date, so the value case still hinges on clinical proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS-986249 CTLA-4 Probody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMS-986249 is one of two CTLA-4 Probody programs in clinical testing, reinforcing CytomX Therapeutics, Inc.'s product development strategy through platform reuse. The asset adds a distinct immuno-oncology option to a pipeline that, as of the latest public filings, included multiple clinical-stage programs and cash of about $167 million. This shows ongoing product creation from the same Probody platform, not a one-off asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBMS-986288 CTLA-4 Probody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBMS-986288 is CytomX Therapeutics, Inc.'s second CTLA-4 Probody, so CytomX now has 2 assets in the same checkpoint class. That depth supports product development in current oncology markets and lowers reliance on a single CTLA-4 program.\u003c\/p\u003e\n\u003cp\u003eFor Ansoff, this is a clear product-development move: 1 target class, more pipeline shots, and more clinical optionality without leaving the oncology base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 CTLA-4 Probody assets\u003c\/li\u003e\n\u003cli\u003eSame oncology class\u003c\/li\u003e\n\u003cli\u003eDeeper pipeline coverage\u003c\/li\u003e\n\u003cli\u003eProduct-development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProbody platform engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. treats Probody as a platform-led product engine, not a single-asset bet. The conditionally activated antibody design keeps activity focused on tumor tissue, which supports new pipeline flow from the same core technology; as of the latest public filings, CytomX reported only about $20 million in cash and cash equivalents, so platform reuse matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform-led growth, not asset-by-asset only\u003c\/li\u003e\n\u003cli\u003eTargeted activation can reduce off-tumor risk\u003c\/li\u003e\n\u003cli\u003eCash constraint raises reuse pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCytomX Deepens Its Probody Oncology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. uses product development by adding new oncology assets to its Probody platform: CX-2043, CX-904, BMS-986249, and BMS-986288. This deepens the same cancer market with 2 CTLA-4 programs and a conditionally activated EGFR and epCAM pipeline, while cash was about $167 million in the latest filing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCX-2043\u003c\/td\u003e\n\u003ctd\u003eepCAM ADC\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCX-904\u003c\/td\u003e\n\u003ctd\u003eEGFR Probody\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS-986249\u003c\/td\u003e\n\u003ctd\u003eCTLA-4 Probody\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS-986288\u003c\/td\u003e\n\u003ctd\u003eCTLA-4 Probody\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADC and Probody mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is diversifying its cancer pipeline across two modalities: antibody-drug conjugates and Probody therapeutics. This mix lowers reliance on a single product type and spreads clinical risk across separate drug platforms. In Ansoff terms, it is related diversification within oncology, using 2 distinct therapeutic formats to widen future shots on goal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD166 CTLA-4 epCAM EGFR targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is diversifying across 4 targets: CD166, CTLA-4, epCAM, and EGFR. That widens the science base and reduces reliance on one biology or one trial readout. It also spreads clinical risk across distinct tumor settings, which can improve the odds that at least one program advances.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreast cancer melanoma solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. spans breast cancer, metastatic melanoma, and other solid tumors, so its pipeline is not tied to one cancer niche. That fits diversification in Ansoff Matrix terms, since breast cancer alone had about 2.3 million new cases worldwide in 2022 and solid tumors make up most oncology demand. A wider mix can spread clinical risk and broaden the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHematologic and solid tumor mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is widening CX-2029 beyond solid tumors: it is also being studied in diffuse large B-cell lymphoma, the most common aggressive non-Hodgkin lymphoma, with about 18,000 U.S. cases a year. That adds a hematologic setting to a pipeline still led by solid-tumor assets. The mix lowers single-indication risk and broadens clinical readout points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSolid tumors plus lymphoma\u003c\/li\u003e\n\u003cli\u003eDLBCL adds a new cancer class\u003c\/li\u003e\n\u003cli\u003eBroader data can cut concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSix-pharma partner model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. uses a six-partner base with AbbVie, Amgen, Bristol Myers Squibb, ImmunoGen, Pfizer, and Astellas, so funding and development risk is not tied to one buyer. In Ansoff terms, this is diversification through parallel pharma networks, which broadens program reach and can speed advancement across more than 6 large R\u0026amp;D channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 named pharma collaborators\u003c\/li\u003e\n\u003cli\u003eFunds and risk spread across partners\u003c\/li\u003e\n\u003cli\u003eAdvancement can move in parallel\u003c\/li\u003e\n\u003cli\u003eLower single-partner dependency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCytomX’s Diversified Oncology Bet Widens Its Shot at Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCytomX Therapeutics, Inc. is diversifying within oncology by pairing 2 modalities, 4 targets, and both solid tumors and DLBCL, which spreads clinical risk and widens its shot list. Its partner base of 6 large pharma names also reduces dependence on one funding path.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAxis\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eModalities\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargets\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDLBCL U.S. cases\u003c\/td\u003e\n\u003ctd\u003e18,000\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234174673161,"sku":"ctmx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ctmx-ansoff-matrix.webp?v=1785716064","url":"https:\/\/dcfanalyst.com\/products\/ctmx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}